Modulation of NKG2D ligand expression and metastasis in tumors by spironolactone via RXRγ activation.
about
TOX2 regulates human natural killer cell development by controlling T-BET expressionSpironolactone use and risk of incident cancers: a retrospective, matched cohort study.Present and Future of Allogeneic Natural Killer Cell TherapyNatural killer cell therapy in children with relapsed leukemia.T Cells Engineered With Chimeric Antigen Receptors Targeting NKG2D Ligands Display Lethal Toxicity in Mice.Combination immune therapies to enhance anti-tumor responses by NK cells.KRT19 directly interacts with β-catenin/RAC1 complex to regulate NUMB-dependent NOTCH signaling pathway and breast cancer properties.Attribution of NKG2DL to the inhibition of early stage allogeneic tumors in mice.The DNA Damage Response: A Common Pathway in the Regulation of NKG2D and DNAM-1 Ligand Expression in Normal, Infected, and Cancer Cells.New approaches for the immunotherapy of acute myeloid leukemia.PCNA-Ub polyubiquitination inhibits cell proliferation and induces cell-cycle checkpoints.NKG2D Signaling Leads to NK Cell Mediated Lysis of Childhood AMLAn overview of the potential strategies for NK cell-based immunotherapy for acute myeloid leukemia.NKG2D- and T-cell receptor-dependent lysis of malignant glioma cell lines by human γδ T cells: Modulation by temozolomide and A disintegrin and metalloproteases 10 and 17 inhibitorsResveratrol promotes MICA/B expression and natural killer cell lysis of breast cancer cells by suppressing c-Myc/miR-17 pathway.Spironolactone-induced degradation of the TFIIH core complex XPB subunit suppresses NF-κB and AP-1 signalling.In-depth immunophenotyping of patients with glioblastoma multiforme: Impact of steroid treatment.Immunosenescence and Immunotherapy in Elderly Acute Myeloid Leukemia Patients: Time for a Biology-Driven Approach
P2860
Q28854590-3603806C-8F3D-4BB3-B2B0-00AF2F3B70AEQ34542518-210C359E-FE40-428B-A7BA-855C4DFB0620Q35677351-8BA36A57-02EB-4C70-A7EE-38B16897178DQ36251948-EAD7D555-A4BC-4040-A573-B32053646E6CQ36757142-4E098078-E941-43D4-827C-C918977A8A0BQ37408550-09C8A083-100E-4F11-81C9-81EFA559FABCQ37609828-C79D1D3D-98C1-4953-A947-95BD2174C7BCQ37696132-4BCED263-5B81-4D07-B2C1-3309BA47F8F3Q38178966-A0B0326F-9EE8-4DE8-90A8-02E38724E076Q38482206-692EF321-E2F4-4DD2-B610-1957D8E681CBQ38740304-917DF495-C597-41CF-9BDE-7A63661F60C6Q38847073-F4AF68D6-682E-4FF6-9EC4-B4BED4061FCFQ38930242-7065384F-43F2-4178-B158-743BBE5F4E12Q39798606-400EC9F4-7C82-4B73-BE70-C4F0128853D7Q42371577-55BCC906-6556-496A-8084-2EE948404CC8Q47647088-E790F5AE-D124-4AEF-83A1-15A01357DC0CQ52780147-718925D5-3D51-4C2E-A3D4-C611F9FD2251Q56378931-80F61DB8-20E4-4E53-AB9A-E2D4892429DA
P2860
Modulation of NKG2D ligand expression and metastasis in tumors by spironolactone via RXRγ activation.
description
2013 nî lūn-bûn
@nan
2013 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
Modulation of NKG2D ligand exp ...... nolactone via RXRγ activation.
@ast
Modulation of NKG2D ligand exp ...... nolactone via RXRγ activation.
@en
type
label
Modulation of NKG2D ligand exp ...... nolactone via RXRγ activation.
@ast
Modulation of NKG2D ligand exp ...... nolactone via RXRγ activation.
@en
prefLabel
Modulation of NKG2D ligand exp ...... nolactone via RXRγ activation.
@ast
Modulation of NKG2D ligand exp ...... nolactone via RXRγ activation.
@en
P2093
P2860
P356
P1476
Modulation of NKG2D ligand exp ...... nolactone via RXRγ activation.
@en
P2093
Laura Janke
Queenie P Vong
Taosheng Chen
Wai-Hang Leung
Wenwei Lin
Wing Leung
P2860
P304
P356
10.1084/JEM.20122292
P407
P577
2013-11-04T00:00:00Z